Page 13 - Flipbook

ICELAND: T SUPPRESSION WITH LEUPROLIDE ACETATE SC

vs. OUTCOME

T LEVEL TIME TO CAUSE-SPECIFIC SURVIVAL TIME TO PSA (CRPC) PROGRESSION

(nmol/L) n % (95% CI) HR (95% CI) p* % (95% CI) HR (95% CI) p*

Minimum

≤ 0.7 311 90.5 (87.2–93.8) 1 99.0 (97.9–100.0) 1

> 0.7− ≤ 1.7 33 86.7 (74.5–100.0) 0.89 (0.4–1.8) 0.849 92.4 (83.3–100.0) 5.06 (1.3–16.1) 0.062
> 1.7 1 100.0 (100.0–100.0) NE 100.0 (100.0–100.0) NE

Median

≤ 0.7 288 90.2 (86.8–93.7) 1 98.9 (97.8–100.0) 1

> 0.7− ≤ 1.7 54 89.1 (80.6–98.9) 0.84 (0.4–1.6) 0.598 95.4 (89.8–100.0) 3.92 (1.2–12.3) 0.083
> 1.7 3 83.3 (56.7–100.0) 2.74 (0.2–12.7) 100.0 (100.0–100.0) NE

Maximum

≤ 0.7 257 90.6 (87.0–94.2) 1 99.2 (98.1–100.0) 1
> 0.7− ≤ 1.7 78 87.8 (80.3–95.5) 1.13 (0.6–1.9) 0.196 96.8 (92.9–100.0) 2.79 (0.8–9.3) 0.165

> 1.7 10 83.3 (59.5–100.0) 3.59 (0.9–10.0) 95.0 (85.7–100.0) 4.57 (0.2–26.8)

Serum T ≤ 0.7 nmol/L  Min 90.1%  Med 83.5%  Max 74.5%

Tombal B, et al. J Urol 2017;198:1054-60
NE Not estimable Tombal B, et al. Ann Oncol 2016;27: 243-65